This report describes a health economic evaluation that investigates the potential cost-effectiveness of an extension of the national vaccination programme for children against human papilloma virus to also include boys. Today, only girls are offered vaccination within the national vaccination programme.
The report, together with 12 other factors, make up the 13 factors that the Public Health Agency of Sweden accounts for when proposing changes in the national vaccination programme to the government. These 13 factors together constitute the basis for making a decision on whether to extend the HPV vaccination programme to boys.
The main target group for this publication is the government of Sweden (the Ministry of Health and Social Affairs). It could also be of interest for health professionals, foreign ministries of health, and public health institutions contemplating sex-neutral vaccination programmes against HPV.
Revision 1, October 2017
The results from the health economic evaluation shows that an introduction of sex-neutral vaccination would imply a cost of 375,000 SEK per gained QALY compared to only vaccinating girls.
The health economic evaluation compared health effects and costs of vaccinating both boys and girls compared to only vaccinating girls. The model used is a so-called extended SIR-model, with a time horizon of 100 years. The analysis takes herd-immunity into account. Costs are made up of direct costs for vaccine and resource use within the healthcare sector and indirect costs in the form of productivity losses. The results are also presented without the inclusion of indirect costs.
If the price of the vaccine was about 85% lower than today's list price (2017), the introduction of sex-neutral vaccination would imply an increase in costs of about 12 million SEK annually, compared to only vaccinating females. In addition, the added cost of school nurses administrating the vaccine would be about 5.6 million SEK annually, given the assumptions in the base case analysis. If two school nurses work together during the vaccination procedure, the cost of administrating the vaccine would increase to about 11.2 million SEK.